Combining Anti-Inflammatory Lipids with Cannabinoids Enhanced Pain Relief in Diabetic Rats | Research

The takeaway

Aspirin-triggered lipoxin A4 reduced diabetic nerve pain in rats, and adding cannabinoid receptor activators amplified the effect.

Pain researchers; scientists studying endocannabinoid-lipid interactions; those following diabetic neuropathy treatment development.

Low-dose ATL + cannabinoid agonists produced augmented pain relief

What the researchers found

Aspirin-triggered lipoxin A4 (ATL) reduced mechanical hyperalgesia in diabetic rats both acutely and cumulatively. Combining low-dose ATL with CB1 or CB2 receptor agonists (ACEA or JWH-133) produced enhanced pain relief beyond what either achieved alone.

Why it matters

Current diabetic neuropathy treatments are often inadequate. This study identifies a potential synergy between the body's natural inflammation-resolving molecules and the endocannabinoid system that could lead to more effective combination therapies.

The numbers in context

ATL at 30 ng produced acute pain relief. Cumulative relief at 1, 3, 10, or 30 ng doses. Low-dose ATL (1 or 3 ng) combined with ACEA or JWH-133 (30 mcg/rat) produced augmented pain relief. ATL reduced anxiety-like but not depressive-like behavior in diabetic rats.

How the study worked

Streptozotocin-induced diabetic rats tested with electronic Von Frey for mechanical pain. ATL administered alone (0.3-30 ng) or combined with intrathecal CB1/CB2 agonists. Assessed locomotion, anxiety-like, and depressive-like behaviors.

What this study cannot tell us

Animal model only. Streptozotocin-induced diabetes may not fully replicate human diabetic neuropathy. Intrathecal drug delivery not practical for routine clinical use. Short-term assessment only.

How to read the evidence

Animal study with novel drug combination; no human data.

When this study was published

2025 study

The bigger picture

The interaction between pro-resolving lipid mediators and the endocannabinoid system suggests these two systems may naturally work together to control pain and inflammation, opening up new combination treatment strategies.

Questions still open

Would this combination work with plant-derived cannabinoids? Could oral formulations achieve similar synergy? What is the mechanism behind the ATL-cannabinoid interaction?

Common questions

What is aspirin-triggered lipoxin A4?

It's a specialized pro-resolving lipid mediator, meaning it's a natural molecule the body produces (triggered by aspirin) that actively resolves inflammation rather than just blocking it.

Why combine it with cannabinoids?

Each system independently modulates pain. The researchers found that combining low doses of both produced better pain relief than either alone, suggesting the systems interact to enhance each other's effects.

Read the original research

Aspirin-triggered lipoxin A4 reduces neuropathic pain and anxiety-like behaviours in male diabetic rats: antinociceptive enhancement by cannabinoid receptor agonists.

European journal of pharmacology, 989, 177254

View on PubMed ↗Publisher’s paper ↗

Citation

Ferreira, Matheus Vinícius; Jesus, Carlos Henrique Alves; Bonfim da Costa, Jaderson Pedro; Oliveira, Gabrielle; Liebl, Bruno; Verri Junior, Waldiceu; Zanoveli, Janaína Menezes; Cunha, Joice Maria da. (2025). Aspirin-triggered lipoxin A4 reduces neuropathic pain and anxiety-like behaviours in male diabetic rats: antinociceptive enhancement by cannabinoid receptor agonists.. European journal of pharmacology, 989, 177254. https://doi.org/10.1016/j.ejphar.2025.177254